By Fineline Cube 
German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August 12, 2025, an exclusive global license and collaboration agreement to co-develop and commercialize Kumquat’s KRAS G12D inhibitor. This strategic partnership combines Kumquat’s innovative drug development capabilities with Bayer’s extensive experience in oncology to advance a promising therapeutic option for patients with KRAS G12D-mutant cancers.
Collaboration Details
Under the terms of the agreement, Kumquat Biosciences will initiate and complete the Phase Ia study for its KRAS G12D inhibitor. Bayer will assume responsibility for all subsequent development and commercialization activities. This collaboration model leverages the strengths of both companies to expedite the drug’s progression from early-stage trials to potential market approval.
Financial Terms
Kumquat Biosciences stands to receive up to $1.3 billion under the agreement. This includes an upfront payment, clinical and commercial milestone payments, and tiered royalties on net sales. Additionally, Kumquat retains an exclusive option to negotiate for profit-and-loss sharing in the U.S., further aligning the interests of both parties in the drug’s success.
Regulatory Progress
Kumquat Biosciences received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of its KRAS G12D inhibitor in July 2025. This regulatory milestone paves the way for the Phase Ia study to proceed, marking a significant step forward in the clinical development of this potential oncology treatment.-Fineline Info & Tech